Feedback / Questions
timbetasin ophthalmic (RGN-259) - ReGenTree
RGN-259: Patent expiry in US in late 2031
(Regenerx)
-
Sep 20, 2017 -
Investor Conference
Patent
•
Dry Eye Disease • Ophthalmology
http://www.regenerx.com/presentations
Sep 20, 2017
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious